ACE-CL-006 : A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

ThreePhase Three

Over 18Age Over 18

Blood<br/>CancersCancer LocationBlood
Cancers

Systemic therapy | Blood / Myeloma / LymphomaChronic Lymphocytic Leukaemia

Trial Overview Read MoreRead more

This phase III trial is evaluating two drugs (acalabrutinib and ibrutinib) for the treatment of patients who have been diagnosed Chronic Lymphocytic Leukemia (CLL).
 

This trial is treating patients with Chronic Lymphocytic Leukaemia.

This is a systemic therapy trial.

You may be excluded from this trial if:

  • You have had certain treatments, surgical procedures or drugs.
  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia

Commercial Sponsor

Acerta Pharma BV

Summary

This study is designed to evaluate PFS endpoint for ACE-196 vs ibrutinib in previously treated chronic lymphocytic leukemia. Potential participants must have ≥ 1 of the following high-risk prognostic factors: ◦Presence of 17p del by central laboratory. ◦Presence of 11q del by central laboratory

Recruiting Hospitals Read MoreRead more

Frankston Hospital
Frankston
Ms Theresa de Man
tdemann@phcn.vic.gov.au
03 9784 7290

PCCTU (Parkville cancer clinical trials unit) *
Parkville
Ms Marian Lieschke
marian.lieschke@petermac.org
03 8559 7140